UCLA's Jonsson Comprehensive Cancer Center : JCCC Member Directory

Antoni Ribas, M.D., Ph.D.

Specialty:

Cancer/Medical Oncology

General Information:

Gender:	Male
Language(s):	English, Spanish

Affiliation(s):

Professor, Department of Medicine, Hematology/Oncology

Director, JCCC Tumor Immunology Program Area

Member, JCCC Signal Transduction and Therapeutics Program Area

Education:

Fellowship:	Hematology/Oncology, UCLA School of Medicine, 1998 - 2001
Residency:	Hospital Vall d'Hebron, 1992 - 1994
Internship:	Medical Oncology, Hospital Vall d'Hebron, 1991 - 1992
Medical Degree:	M.D., Universidad de Barcelona, 1990

Contact Information:

Phone:	(310) 794-4955 Patient appointments
Email:	aribas@mednet.ucla.edu

Practice Information:

Clinical Interest(s):	Melanoma

Scientific Interest(s):

Dr. Antoni Ribas is a physician-scientist conducting laboratory and clinical research focused in malignant melanoma. His research includes:

laboratory and clinical translational research in adoptive cell transfer therapy with T-cell receptor (TCR) engineered lymphocytes
understanding the antitumor activity of CTLA4-blocking antibodies
molecular imaging and advanced immune monitoring for the study of tumor immunotherapy
the laboratory and clinical testing of novel targeted therapies blocking oncogenic events in melanoma and their use as immune sensitizers
the clinical application of nanoparticle delivery of siRNA.

Selected Cancer-Related Publications:

Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010 Apr 15;464(7291):1067-70. Epub 2010 Mar 21.

Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010 Aug 26;363(9):809-19.

Koya RC, Mok S, Comin-Anduix B, Chodon T, Radu CG, Nishimura MI, Witte ON, Ribas A. Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14286-91. Epub 2010 Jul 12.

Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010 Dec 16;468(7326):973-7. Epub 2010 Nov 24.

Comin-Anduix B, Chodon T, Sazegar H, Matsunaga D, Mock S, Jalil J, Escuin-Ordinas H, Chmielowski B, Koya RC, Ribas A. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res. 2010 Dec 15;16(24):6040-8.